Levilactobacillus　brevis　FZU0713,　a　potential　probiotic　previously　isolated　from　the　traditional　brewing　process　of　Hongqu　rice　wine,　may　have　the　beneficial　effects　on　improving　lipid　metabolism.　This　study　aimed　to　evaluate　the　in　vivo　protective　effects　and　possible　mechanism　of　L.　brevis　FZU0713　on　the　disturbance　of　lipid　metabolism　in　hyperlipidemic　rats　fed　a　high-fat　diet　(HFD).　Results　showed　that　oral　administration　of　L.　brevis　FZU0713　could　significantly　inhibit　obesity,　ameliorate　the　lipid　metabolism　disorder,　including　serum/liver　biochemical　parameters　and　hepatic　oxidative　stress　in　HFD-fed　rats.　Histopathological　result　also　indicated　that　dietary　intervention　of　L.　brevis　FZU0713　could　reduce　the　accumulation　of　lipid　droplets　in　liver　induced　by　8　weeks　HFD　feeding.　Furthermore,　L.　brevis　FZU0713　intervention　significantly　increased　the　fecal　levels　of　short-chain　fatty　acids　(SCFAs,　including　acetate,　propionate,　butyrate,　isobutyrate,　valerate　and　isovalerate)　in　HFD-fed　rats,　which　may　be　closely　related　to　the　changes　of　intestinal　microbial　composition　and　metabolic　function.　Intestinal　microbiota　profiling　by　16S　rRNA　gene　sequencing　revealed　that　L.　brevis　FZU0713　intervention　significantly　altered　the　relative　abundance　of　Coprococcus,　Butyricicoccus,　Intestinimonas,　Lachnospiraceae　FCS020　group,　Ruminococcaceae_NK4A214　group,　Ruminococcaceae_UCG-005　and　UCG-014　at　genus　levels.　Based　on　Spearman＇s　rank　correlation　coefficient,　serum　and　liver　lipid　metabolism　related　biochemical　parameters　were　positively　correlated　with　genera　Ruminococcus,　Pediococcus　and　Lachnospiraceae,　but　negatively　correlated　with　genera　Pseudoflavonifractor,　Butyricicoccus　and　Intestinimonas.　Furthermore,　liver　metabolomics　analysis　demonstrated　that　L.　brevis　FZU0713　had　a　significant　regulatory　effect　on　the　composition　of　liver　metabolites　in　hyperlipidemic　rats,　especially　the　levels　of　some　important　biomarkers　involved　in　the　metabolic　pathways　of　arachidonic　acid　metabolism,　primary　bile　acid　biosynthesis,　amino　sugar　and　nucleotide　sugar　metabolism,　taurine　and　hypotaurine　metabolism,　biosynthesis　of　unsaturated　fatty　acid,　fructose　and　mannose　metabolism,　tyrosine　metabolism,　etc.　Additionally,　oral　administration　of　L.　brevis　FZU0713　significantly　regulated　the　mRNA　levels　of　liver　genes　(including　Acat2,　Acox1,　Hmgcr,　Cd36,　Srebp-1c　and　Cyp7a1)　involved　in　lipid　metabolism　and　bile　acid　homeostasis.　In　conclusion,　our　findings　provide　the　evidence　that　L.　brevis　FZU0713　has　the　potential　to　improve　disturbance　of　lipid　metabolism　by　regulating　intestinal　microflora　and　liver　metabonomic　profile.　Therefore,　L.　brevis　FZU0713　may　be　used　as　a　potential　probiotic　strain　to　produce　functional　food　to　prevent　hyperlipidemia.　©　2023